8-K: iTeos Therapeutics to Be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal

iTeos Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $10.047 per share in cash plus a contingent value right, following a unanimous board recommendation.

Summary

• iTeos Therapeutics, Inc. (ITOS) entered into an Agreement and Plan of Merger with Concentra Biosciences, LLC and Concentra Merger Sub VIII, Inc. on July 18, 2025.
• Concentra will acquire all outstanding shares of iTeos common stock through a tender offer for an Offer Price of $10.047 in cash per share (the Cash Amount) plus one Contingent Value Right (CVR).
• The CVR entitles holders to potential future cash payments: (i) 100% of iTeos's closing net cash exceeding $475 million, and (ii) 80% of net proceeds from any disposition of specific iTeos product candidates (EOS-984, EOS-215, preclinical obesity program targeting ENT1 including EOS-518 and EOS-855, and PTPN1/2 inhibiting small molecule program) that occurs within six months following the closing.
• The iTeos Board of Directors unanimously determined the transaction is fair and in the best interests of stockholders and recommended they accept the Offer.
• The tender offer is required to commence as promptly as practicable, and in any event no later than ten (10) business days after July 18, 2025.
• Following the tender offer, Merger Sub will merge into iTeos, with iTeos surviving as a wholly owned subsidiary of Concentra, pursuant to Section 251(h) of the Delaware General Corporation Law (DGCL), which does not require an additional stockholder vote.
• The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, including a minimum tender condition and the availability of at least $475 million in closing net cash.
• Company Stock Options with an exercise price less than the Cash Amount will be cancelled for cash equal to the difference between the Cash Amount and the exercise price, multiplied by the number of shares, plus one CVR per share.
• Unvested Company Stock Options with an exercise price equal to or greater than the Cash Amount, and unvested Company Stock Options not subject to accelerated vesting, will be cancelled for no consideration.
• Restricted Stock Units (RSUs) with accelerated vesting will be cancelled for cash equal to the Cash Amount, plus one CVR.
• Unvested RSUs not subject to accelerated vesting will be cancelled for no consideration.
• The iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Company ESPP) was terminated on July 18, 2025, with all participant accounts to be refunded.
• iTeos Belgium S.A. and GlaxoSmithKline Intellectual Property (No. 4) Limited (GSK) entered into a Mutual Termination Agreement on July 18, 2025, for their Collaboration and License Agreement, requiring iTeos Belgium to pay GSK a one-time termination payment of $32.0 million.

Sentiment

Score: 8

Explanation: The acquisition provides immediate cash value and potential upside through CVRs, with unanimous board approval and no financing condition. The termination of the GSK agreement and associated payment is a known factor. Overall, it's a positive outcome for shareholders, albeit with the inherent speculative nature of CVRs.

Positives

• The iTeos Board of Directors unanimously approved the merger agreement and recommended stockholders accept the offer, indicating strong internal support.
• The acquisition provides immediate cash value of $10.047 per share to stockholders, offering liquidity.
• Contingent Value Rights (CVRs) offer potential additional upside based on future net cash exceeding $475 million and 80% of net proceeds from dispositions of certain product candidates within a six-month period post-closing.
• The transaction is not subject to a financing condition, reducing uncertainty regarding deal completion.
• The merger is structured to close quickly via a tender offer and Section 251(h) of the DGCL, avoiding a potentially lengthy stockholder meeting process.
• Directors and executive officers, holding approximately 0.6% of outstanding shares, have entered into support agreements to tender their shares, aligning management interests with the deal.

Negatives

• The CVRs are non-transferable, limiting liquidity for holders and potentially making their value difficult to realize immediately.
• There is no assurance that CVR holders will receive any payments, as dispositions of CVR products may not occur or generate sufficient net proceeds.
• The CVRs do not represent any equity or ownership interest in Concentra or its affiliates, nor do they have voting or dividend rights.
• A termination fee of $8.4 million is payable by iTeos under certain circumstances, including if it enters into a superior proposal, which could be a deterrent to other bidders.
• iTeos is required to reimburse Concentra up to $0.5 million in expenses if Concentra terminates due to iTeos's closing net cash being less than $475 million.
• The GlaxoSmithKline (GSK) collaboration and license agreement was terminated, requiring a $32.0 million payment from iTeos Belgium to GSK, which impacts iTeos's cash position.
• Unvested Company Stock Options with an exercise price equal to or greater than the Cash Amount, and unvested Company Restricted Stock Units not subject to accelerated vesting, will be cancelled for no consideration, potentially disadvantaging some equity holders.

Risks

• Uncertainties exist regarding the timing of the Offer and Merger.
• There are uncertainties as to how many of iTeos stockholders will tender their stock in the Offer.
• The possibility that various closing conditions for the transaction may not be satisfied or waived, including that iTeos may not satisfy the minimum closing net cash condition of $475 million.
• A governmental entity may prohibit or delay the consummation of the transaction.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the Merger Agreement, including circumstances requiring iTeos to pay a termination fee.
• Significant transaction costs may be incurred.
• Activities related to the CVR Agreement may not result in any value to iTeos stockholders.
• The possibility that competing offers will be made could introduce uncertainty or delays.
• Stockholder litigation in connection with the proposed transactions may result in significant costs of defense, indemnification, and liability.
• Risks of unexpected costs, delays, or other unexpected hurdles could impact the transaction.
• Other factors as set forth in iTeos's Annual Report on Form 10-K filed with the SEC on March 5, 2025, and Quarterly Report on Form 10-Q filed with the SEC on April 28, 2025, and other reports filed with the SEC.

Future Outlook

The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, including the minimum tender condition and the net cash condition. The Contingent Value Rights (CVRs) offer potential future payments contingent on iTeos's net cash exceeding $475 million and future dispositions of specific product candidates within a six-month period post-closing. The company will also complete wind-down activities related to the terminated GSK agreement.

Management Comments

• The iTeos board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all iTeos stockholders and has approved the merger agreement and related transactions.

Industry Context

This acquisition represents a strategic move by Concentra Biosciences to acquire iTeos Therapeutics, a company with a portfolio of product candidates in oncology and preclinical obesity programs. The use of a Contingent Value Right (CVR) is common in biotech acquisitions, especially for companies with early-stage or unpartnered assets, allowing the acquirer to cap upfront costs while providing potential upside to selling shareholders based on future asset performance or monetization. The termination of the GSK collaboration suggests a shift in iTeos's strategic partnerships prior to the acquisition, potentially streamlining its asset portfolio for the new owner.

Comparison to Industry Standards

• The use of a CVR in a biotech acquisition is a standard mechanism to bridge valuation gaps for pipeline assets, similar to deals involving companies like Acceleron Pharma (acquired by Merck) or Synlogic (acquired by Roche).
• The 80% share of net proceeds from CVR product dispositions is a relatively high percentage for selling shareholders, potentially indicating confidence in the value of these assets or a strong negotiation position by iTeos.
• The $475 million net cash condition is a significant financial threshold, ensuring the acquiring entity receives a company with a robust cash position, which is a key factor in biotech valuations.
• The termination fee of $8.4 million, representing approximately 2% of the equity value (based on 44.17 million shares * $10.047/share = ~$443 million), is within the typical range (1-4%) for public company mergers, balancing deal protection for Concentra with flexibility for iTeos to pursue a superior offer.
• The mutual termination of the GSK agreement and the associated $32 million payment is a notable event, as large pharma collaborations are often key value drivers. This suggests a strategic decision to unencumber certain assets or streamline operations prior to the acquisition, potentially making iTeos more attractive to Concentra.

Management Changes

Corporate Governance

Legal Proceedings

• No material Proceeding is pending or, to the knowledge of the Company, threatened against the Company or its subsidiaries that has resulted in, or would reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect.
• No investigations, suits, claims, actions or proceedings are pending, or to the knowledge of the Company, threatened against the Company or its subsidiaries alleging any material violation by the Company, its subsidiaries or the Company Products of any Health Law.
• There is a risk of stockholder litigation in connection with the proposed transactions, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Tang Capital Partners, LP (Guarantor), a Delaware limited partnership, delivered a limited guaranty to iTeos, as a condition and inducement for iTeos to enter the Merger Agreement. Tang Capital Management, LLC is the sole manager of Parent and the general partner of Guarantor.
• Certain iTeos directors and executive officers entered into tender and support agreements with Concentra and Merger Sub, agreeing to tender their shares, which comprise approximately 0.6% of the outstanding shares of Common Stock.

Stakeholder Impact

• Shareholders: Will receive $10.047 in cash per share plus a CVR, providing immediate liquidity and potential future upside. Treatment of equity awards varies based on vesting and exercise price, with some being cancelled for no consideration.
• Employees: The Company ESPP is terminated with refunds. Certain employees with accelerated vesting equity awards will receive cash and CVRs. Post-merger, group health plans will be maintained for 18 months, and the Company Retirement Plan will be terminated after a true-up contribution. Management changes are expected at the Effective Time.
• Customers/Suppliers: No direct impact on customers or suppliers is explicitly detailed, but the wind-down process and termination of the GSK agreement may affect existing relationships or future business engagements.
• Creditors: The company's indebtedness is a factor in the Closing Net Cash calculation, which directly impacts the value of the CVRs. The transaction is not subject to a financing condition, which may provide some assurance to creditors.
• Regulatory Authorities: The transaction requires various filings with the SEC and compliance with applicable Health Laws and Regulatory Authorizations.

Next Steps

• Concentra to commence the tender offer by August 1, 2025.
• iTeos to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Merger Sub to merge with iTeos following the successful completion of the tender offer.
• iTeos's securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time, and in any event no more than ten (10) days after the Merger Closing Date.
• iTeos Belgium and GSK are required to complete certain ongoing activities related to the wind-down and completion of clinical trials, data migration, and scientific/medical publications related to the terminated agreement.
• Parent and Merger Sub will use commercially reasonable efforts to spend up to $350,000 on CVR product maintenance and disposition efforts during the Disposition Period.
• Parent and Merger Sub will continue to seek partnerships or investments for the CVR Products during the Disposition Period.
• The Company Retirement Plan will be terminated as soon as administratively practicable following a true-up contribution to participant accounts.

Key Dates

Recommendation

Keywords

iTeos Therapeutics, Concentra Biosciences, Merger Agreement, Tender Offer, Contingent Value Right, CVR, Acquisition, Biotech, Pharmaceutical, Oncology, EOS-984, EOS-215, ENT1, TREM2, PTPN1/2, Corporate Action, SEC Filing, ITOS, Biopharma